DK3383385T3 - Melflufen-doseringsregimer for cancer - Google Patents

Melflufen-doseringsregimer for cancer Download PDF

Info

Publication number
DK3383385T3
DK3383385T3 DK16805792.5T DK16805792T DK3383385T3 DK 3383385 T3 DK3383385 T3 DK 3383385T3 DK 16805792 T DK16805792 T DK 16805792T DK 3383385 T3 DK3383385 T3 DK 3383385T3
Authority
DK
Denmark
Prior art keywords
cancer
dosage regimens
melflufen
melflufen dosage
regimens
Prior art date
Application number
DK16805792.5T
Other languages
English (en)
Other versions
DK3383385T4 (da
Inventor
Jakob Lindberg
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3383385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Application granted granted Critical
Publication of DK3383385T3 publication Critical patent/DK3383385T3/da
Publication of DK3383385T4 publication Critical patent/DK3383385T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK16805792.5T 2015-12-01 2016-12-01 Melflufen-doseringsregimer for cancer DK3383385T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (2)

Publication Number Publication Date
DK3383385T3 true DK3383385T3 (da) 2020-10-12
DK3383385T4 DK3383385T4 (da) 2023-11-06

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16805792.5T DK3383385T4 (da) 2015-12-01 2016-12-01 Melflufen-doseringsregimer for cancer

Country Status (26)

Country Link
US (2) US20180369141A1 (da)
EP (3) EP3750534A1 (da)
JP (2) JP6878431B2 (da)
KR (2) KR102279629B1 (da)
CN (1) CN108289876A (da)
AU (2) AU2016363591B2 (da)
BR (1) BR112018010012A8 (da)
CA (1) CA3003102C (da)
CY (1) CY1123469T1 (da)
DK (1) DK3383385T4 (da)
ES (1) ES2828033T5 (da)
FI (1) FI3383385T4 (da)
GB (1) GB201521217D0 (da)
HR (1) HRP20201632T4 (da)
HU (1) HUE051525T2 (da)
IL (2) IL301019A (da)
LT (1) LT3383385T (da)
MX (2) MX2018006706A (da)
PL (1) PL3383385T5 (da)
PT (1) PT3383385T (da)
RS (1) RS60986B2 (da)
RU (2) RU2020134307A (da)
SG (1) SG11201803551YA (da)
SI (1) SI3383385T2 (da)
WO (1) WO2017093443A1 (da)
ZA (1) ZA201802816B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021007060A2 (pt) * 2018-10-18 2021-07-20 Oncopeptides Ab compostos contendo deutério
CN114025753A (zh) * 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
WO2023281007A1 (en) * 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
LT3656393T (lt) * 2011-04-28 2022-12-12 Oncopeptides Ab Liofilizuoti citotoksinių dipeptidų preparatai
WO2014065741A1 (en) 2012-10-22 2014-05-01 Parker Hannifin Manufacturing Sweden Ab Joystick
EP2928463B1 (en) * 2012-10-26 2019-11-20 Oncopeptides AB Lyophilized preparations of melphalan flufenamide
CN105338973A (zh) * 2013-04-08 2016-02-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症

Also Published As

Publication number Publication date
ZA201802816B (en) 2021-07-28
PL3383385T5 (pl) 2023-12-18
KR102279629B1 (ko) 2021-07-20
EP3383385B1 (en) 2020-07-29
PT3383385T (pt) 2020-10-26
HUE051525T2 (hu) 2021-03-01
EP3383385A1 (en) 2018-10-10
BR112018010012A2 (pt) 2018-11-21
SI3383385T1 (sl) 2020-11-30
KR20180087254A (ko) 2018-08-01
RU2734930C2 (ru) 2020-10-26
CA3003102A1 (en) 2017-06-08
CY1123469T1 (el) 2022-03-24
MX2021008738A (es) 2021-08-24
FI3383385T4 (fi) 2023-11-01
DK3383385T4 (da) 2023-11-06
HRP20201632T1 (hr) 2021-01-08
EP3383385B2 (en) 2023-09-06
PL3383385T3 (pl) 2021-05-04
ES2828033T5 (es) 2024-04-04
US20180369141A1 (en) 2018-12-27
JP6878431B2 (ja) 2021-05-26
AU2021200436A1 (en) 2021-02-25
GB201521217D0 (en) 2016-01-13
RU2018123718A (ru) 2020-01-09
RS60986B1 (sr) 2020-11-30
CA3003102C (en) 2022-09-13
EP3903777A1 (en) 2021-11-03
AU2016363591B2 (en) 2020-12-10
MX2018006706A (es) 2018-08-01
NZ742548A (en) 2023-10-27
WO2017093443A1 (en) 2017-06-08
IL301019A (en) 2023-05-01
ES2828033T3 (es) 2021-05-25
US20220047507A1 (en) 2022-02-17
JP2019501881A (ja) 2019-01-24
JP2021088560A (ja) 2021-06-10
IL259101A (en) 2018-06-28
LT3383385T (lt) 2020-12-28
HRP20201632T4 (hr) 2023-11-10
RS60986B2 (sr) 2023-12-29
BR112018010012A8 (pt) 2019-02-26
CN108289876A (zh) 2018-07-17
RU2020134307A (ru) 2020-11-27
KR20210092327A (ko) 2021-07-23
RU2018123718A3 (da) 2020-04-02
SI3383385T2 (sl) 2024-01-31
AU2016363591A1 (en) 2018-06-28
EP3750534A1 (en) 2020-12-16
SG11201803551YA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
DK3265421T3 (da) Doseringssystem
DK3310231T3 (da) Doseringsindretning
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
SI3347054T1 (sl) Režimi doziranja konjugatov zdravil proti TF protitelesu
DK3383385T3 (da) Melflufen-doseringsregimer for cancer
DK3363428T3 (da) Perfusionsdoseringsform
DK3393478T3 (da) Kombinationsterapi
DK3283058T3 (da) Ribociclib-tablet
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
DK3359555T3 (da) Doseringsplaner
DK3126791T3 (da) Doseringsanordning
DK3215223T3 (da) Buprenorphindoseringsskemaer
KR20180084810A (ko) 정제 세트
DK3281641T3 (da) Adjuvans til cancervacciner
ITUB20152349A1 (it) Metodo di dosaggio autocalibrato
DK3329004T3 (da) Terapeutiske oligonukleotider
DK3277325T3 (da) Kombinationsimmunterapi for cancer
DK3288967T3 (da) Farmaceutisk forbindelse
DK3288966T3 (da) Farmaceutisk forbindelse
DK3426574T3 (da) Hånddoseringspistol
TH1501007353A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
ITUB20152543A1 (it) Riflettore per radiazioni elettromagnetiche
UA31512S (uk) Сірник